Abstract:• NLRP3 inflammasome is activated with increased NLRP3 acetylation in Tauopathy transgenic mice and AD patients. • Tau promotes NLRP3 acetylation and inflammasome activation dependent on K18 acetyltransferase activity domain. • Tau directly acetylates NLRP3 at K21, K22 and K24 site at its PYD domain and thereby induce inflammasome activation in vitro. • Tau overexpression in mouse hippocampal CA1 neurons induces cognitive impairment, Tau transmission to microglia and microgliosis with NLRP3 acetylation and inflammasome activation. • Competitive binding of a designed TNB peptide to block the interaction of Tau with NLRP3 inhibits the NLRP3 acetylation and downstream inflammasome activation in microglia, thereby alleviating cognitive impairment in mice. Background Alzheimer's disease (AD) and related Tauopathies are characterised by the pathologically hyperphosphorylated and aggregated microtubule‐associated protein Tau, which is accompanied by neuroinflammation mediated by activated microglia. However, the role of Tau pathology in microglia activation or their causal relationship remains largely elusive. Methods The levels of nucleotide‐binding oligomerisation domain (NOD)‐like receptor pyrin domain containing 3 (NLRP3) acetylation and inflammasome activation in multiple cell models with Tau proteins treatment, transgenic mice with Tauopathy, and AD patients were measured by Western blotting and enzyme‐linked immunosorbent assay. In addition, the acetyltransferase activity of Tau and NLRP3 acetylation sites were confirmed using the test‐tube acetylation assay, co‐immunoprecipitation, immunofluorescence (IF) staining, mass spectrometry and molecular docking. The Tau‐overexpressing mouse model was established by overexpression of human Tau proteins in mouse hippocampal CA1 neurons through the adeno‐associated virus injection. The cognitive functions of Tau‐overexpressing mice were assessed in various behavioural tests, and microglia activation was analysed by Iba‐1 IF staining and [18F]‐DPA‐714 positron emission tomography/computed tomography imaging. A peptide that blocks the interaction between Tau and NLRP3 was synthesised to determine the in vitro and in vivo effects of Tau–NLRP3 interaction blockade on NLRP3 acetylation, inflammasome activation, microglia activation and cognitive function. Results Excessively elevated NLRP3 acetylation and inflammasome activation were observed in 3xTg‐AD mice, microtubule‐associated protein Tau P301S (PS19) mice and AD patients. It was further confirmed that mimics of 'early' phosphorylated‐Tau proteins which increase at the initial stage of diseases with Tauopathy, including TauT181E, TauS199E, TauT217E and TauS262E, significantly promoted Tau–K18 domain acetyltransferase activity‐dependent NLRP3 acetylation and inflammasome activation in HEK293T and BV‐2 microglial cells. In addition, Tau protein could directly acetylate NLRP3 at the K21, K22 and K24 sites at its PYD domain and thereby induce inflammasome activation in vitro. Overexpression of human Tau proteins in mouse hippocampal CA1 neurons resulted in impaired cognitive function, Tau transmission to microglia and microgliosis with NLRP3 acetylation and inflammasome activation. As a targeted intervention, competitive binding of a designed Tau–NLRP3‐binding blocking (TNB) peptide to block the interaction of Tau protein with NLRP3 inhibited the NLRP3 acetylation and downstream inflammasome activation in microglia, thereby alleviating microglia activation and cognitive impairment in mice. Conclusions In conclusion, our findings provide evidence for a novel role of Tau in the regulation of microglia activation through acetylating NLRP3, which has potential implications for early intervention and personalised treatment of AD and related Tauopathies.

The Acetylation of Tau Inhibits Its Function and Promotes Pathological Tau Aggregation.

A Unique Tau Conformation Generated by an Acetylation-Mimic Substitution Modulates P301S-dependent Tau Pathology and Hyperphosphorylation.

Hyperacetylation mimetics within the tau filament core inhibits prion-like propagation of misfolded tau

An acetylation–phosphorylation switch that regulates tau aggregation propensity and function

Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss

Molecular Insights into the Differential Effects of Acetylation on the Aggregation of Tau Microtubule-Binding Repeats

Deciphering the Effect of Lysine Acetylation on the Misfolding and Aggregation of Human Tau Fragment (171)IPAKTPPAPK(180) Using Molecular Dynamic Simulation and the Markov State Model

Critical Role of Acetylation in Tau-Mediated Neurodegeneration and Cognitive Deficits

Acetylated tau exacerbates learning and memory impairment by disturbing with mitochondrial homeostasis

Argyrophilic Grain Disease Differs from Other Tauopathies by Lacking Tau Acetylation

Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice

Phosphorylation and O-GlcNAcylation of the PHF-1 Epitope of Tau Protein Induce Local Conformational Changes of the C-Terminus and Modulate Tau Self-Assembly Into Fibrillar Aggregates

Acetylation encodes Tau aggregation

Tau induces inflammasome activation and microgliosis through acetylating NLRP3

Identification of Aggregation Mechanism of Acetylated PHF6* and PHF6 Tau Peptides Based on Molecular Dynamics Simulations and Markov State Modeling.

Development and characterization of novel anti-acetylated tau monoclonal antibodies to probe pathogenic tau species in Alzheimer's disease

Phosphorylation of Tau R2 Repeat Destabilizes Its Binding to Microtubules: A Molecular Dynamics Simulation Study

Human tau accumulation promotes glycogen synthase kinase-3β acetylation and thus upregulates the kinase: A vicious cycle in Alzheimer neurodegeneration

An HDAC6-dependent Surveillance Mechanism Suppresses Tau-Mediated Neurodegeneration and Cognitive Decline

Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP

Anti-acetylated-tau immunotherapy is neuroprotective in tauopathy and brain injury